NovoCure
NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a proprietary biophysical therapy delivered through three FDA-approved wearable devices (Optune Gio, Optune Lua, Optune Pax) for glioblastoma, non-small cell lung cancer, and pancreatic cancer patients. The company serves 4,620 active patients globally through direct field sales and reimbursement-based device distribution.
- Company typePublic
- Founded2000
- HeadquartersZug, Switzerland
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
NovoCure firmographics
Firmographics- Name
- NovoCure
- Legal name
- Novocure GmbH
- Website
- https://novocure.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a proprietary biophysical therapy delivered through three FDA-approved wearable devices (Optune Gio, Optune Lua, Optune Pax) for glioblastoma, non-small cell lung cancer, and pancreatic cancer patients. The company serves 4,620 active patients globally through direct field sales and reimbursement-based device distribution.
- Ownership category
- akta.pro rank
NovoCure industry classification
Industry- Product category
- Oncology Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
- akta.pro secondary industries
- Medical Oncology (HLAKAFAB), Neuro-oncology (HLAKAIAL)
Keywords
Where NovoCure is headquartered
LocationHeadquarters
- HQ city
- Zug
- HQ country
- Switzerland
- HQ region
- Europe
Offices10 records
Markets served
NovoCure business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- TTFields Medical Device Sales and Related Services: Novocure generates revenue through the sale and rental of its TTFields therapy devices (Optune Gio, Optune Lua, Optune Pax) and related services. The company provides devices to patients through healthcare providers and directly, with revenue driven by active patient counts and reimbursement from Medicare, Medicare Advantage, and commercial payers.
- International Market Expansion: Revenue growth driven by international expansion with active patient growth of 10% in Germany, 19% in France, and 29% in Japan. Japan approved National Health Insurance reimbursement for Optune Lua in March 2026, expanding commercial footprint in Asia-Pacific.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Pay-as-you-go | Reimbursement-based pricing through Medicare, Medicare Advantage, and commercial insurance |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
NovoCure product offering
Product offeringCore offering
NovoCure develops and commercializes Tumor Treating Fields (TTFields) therapy delivered via FDA-approved wearable medical devices that apply alternating electric fields to disrupt cancer cell division in solid tumors. The company sells three device brands—Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer, and Optune Pax for pancreatic cancer—used in combination with standard chemotherapy or immunotherapy. Revenue is generated through device sales and rental reimbursed by Medicare and commercial payers.
Product overview
NovoCure offers a portfolio of three FDA-approved wearable medical devices—Optune Gio, Optune Lua, and Optune Pax—all based on its proprietary Tumor Treating Fields (TTFields) platform technology. These portable, non-invasive devices deliver alternating electric fields at cancer-specific frequencies to disrupt cell division in solid tumors. Optune Gio targets glioblastoma, Optune Lua addresses non-small cell lung cancer, and Optune Pax treats pancreatic cancer, each used in combination with standard chemotherapy or immunotherapy regimens.
Differentiator
Problem solved
Functional benefit
Brands
- Optune Gio: Tumor Treating Fields device for glioblastoma
- Optune Lua
- Optune Pax
Products and services
- Optune Gio A wearable medical device that delivers Tumor Treating Fields (TTFields) to treat adult patients with newly diagnosed and recurrent glioblastoma. The device uses arrays placed on the scalp to deliver alternating electric fields that disrupt cancer cell division.
- Optune Lua A wearable medical device delivering TTFields for non-small cell lung cancer (NSCLC). Approved for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent NSCLC who have progressed after platinum-based chemotherapy.
- Optune Pax A portable, non-invasive device delivering TTFields to the abdomen for treating adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. FDA-approved in February 2026 as the first new treatment for this indication in nearly 30 years.
- Tumor Treating Fields (TTFields) Therapy Platform The proprietary platform technology underlying NovoCure's commercial products. Uses alternating electric fields at specific frequencies (100-300 kHz) to exert physical forces on electrically charged components of cancer cells, disrupting mitosis and cell division while sparing healthy cells.
Quantifiable outcome
- 16.2 months vs 14.2 months median OS in pancreatic cancer (HR 0.82, p=0.037)
- +4 more outcomes
Companies that use NovoCure
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
NovoCure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
NovoCure partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- AACR-Novocure TTFields GrantminorAACR-Novocure $350,000 TTFields grant for cancer research funding as part of OncoGrants roundup of cancer research funding opportunities.
- New Hampshire Life Sciences (NHLS)minorNovocure joined New Hampshire Life Sciences as a founding member in January 2024. NHLS is the state's first industry-led life sciences association dedicated to improving patient lives and establishing New Hampshire as a leading life sciences hub. Novocure's North American headquarters has been in Portsmouth, NH since 2006.
- Novo NordiskminorNovo Nordisk also joined as a founding member of New Hampshire Life Sciences alongside Novocure. Both companies are global healthcare companies based in the region committed to championing New Hampshire's life sciences sector.
- Elevance HealthcoreElevance Health secured first major payer coverage policy for Optune Pax within seven weeks of FDA approval, covering more than 30 million lives. This payer partnership is critical for patient access and commercial success of the pancreatic cancer therapy.
Scale indicators13 records
Recent moves8 records
Expansion highlights5 records
NovoCure competitors and assessment
Company assessmentDirect peers
- Elekta: Swedish manufacturer of radiation therapy and radiosurgery equipment (Gamma Knife, linear accelerators) for cancer treatment. Elekta is a direct competitor in the oncology device space, treating similar solid tumor patient populations (including brain tumors) with a different but functionally adjacent modality (radiation vs. electric fields).
- Varian Medical Systems: Now a Siemens Healthineers business, Varian is a global leader in radiation oncology devices and software. It competes directly with NovoCure for hospital and oncology clinic capital equipment budgets, treating similar solid tumor patient populations with a different modality.
- Accuray Incorporated: US-based developer of robotic radiation therapy systems (CyberKnife, TomoTherapy) used to treat solid tumors. Accuray is comparable to NovoCure in oncology device commercialization model, hospital sales channels, and focus on hard-to-treat cancers including brain tumors.
- ViewRay Technologies: Developer of MRI-guided radiation therapy systems (MRIdian) for cancer treatment. ViewRay targets similar oncology indications and patient populations as NovoCure, with both companies competing to displace or complement standard radiation and chemotherapy regimens.
Emerging players
- IBA (Ion Beam Applications): Belgian company specializing in proton therapy solutions for cancer treatment. IBA competes in the advanced oncology device space with a focus on high-precision radiation delivery, partially overlapping with NovoCure's positioning in novel treatment modalities for solid tumors.
- Celsion Corporation: US oncology company developing novel treatment modalities including ThermoDox (heat-activated liposomal doxorubicin) for liver cancer and other solid tumors. Celsion is comparable as a smaller oncology company pursuing novel delivery technologies for difficult-to-treat cancers.
Broad incumbents
- Merck & Co. Global pharmaceutical leader with Keytruda (pembrolizumab) dominating the checkpoint inhibitor space. Merck competes with NovoCure indirectly through immunotherapy combinations in NSCLC and pancreatic cancer, where TTFields is being tested as a complementary modality.
- Bristol-Myers Squibb: Major oncology pharmaceutical company with Opdivo (nivolumab) and Yervoy (ipilimumab) leading its immuno-oncology franchise. BMS competes with NovoCure in NSCLC and other solid tumor indications where TTFields is being positioned as a complementary modality to checkpoint inhibitors.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
NovoCure social profiles
Digital presenceNovoCure compliance and trust
Trust signalCompliance4 records
NovoCure financial estimates
Financial estimateRevenue estimate
Valuation estimate
NovoCure leadership team
Management profileNumber of profiles
Profiles10 records
NovoCure subsidiaries and ownership
Company hierarchySubsidiaries7 records
NovoCure funding detail
Funding detailFunding overview
Funding rounds7 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NovoCure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NovoCure
What does NovoCure do?
NovoCure develops and commercializes Tumor Treating Fields (TTFields) therapy delivered via FDA-approved wearable medical devices that apply alternating electric fields to disrupt cancer cell division in solid tumors. The company sells three device brands—Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer, and Optune Pax for pancreatic cancer—used in combination with standard chemotherapy or immunotherapy. Revenue is generated through device sales and rental reimbursed by Medicare and commercial payers.
Is NovoCure a public or private company?
NovoCure is a public company. It is classified as public and is currently operating.
When was NovoCure founded?
NovoCure was founded in 2000. It employs 1,001 to 5,000 people.
Where is NovoCure based?
NovoCure is headquartered in Zug, Switzerland, in the Europe region.
How does NovoCure make money?
Two revenue lines are on record. TTFields Medical Device Sales and Related Services are the primary driver. The others are international Market Expansion.
Who are NovoCure's main competitors?
Direct peers on record are Elekta, Varian Medical Systems, Accuray Incorporated and ViewRay Technologies. Emerging players are IBA (Ion Beam Applications) and Celsion Corporation. Broad incumbents are Merck & Co. and Bristol-Myers Squibb.
Does NovoCure have an API?
No public API is recorded for NovoCure.
What industry is NovoCure in?
NovoCure's product category is Oncology Medical Devices. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 339113 and its SIC code is 3841.